Navigation Links
Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
Date:2/19/2009

Transaction Value in Excess of $10 Million; Access Gains Second

Source Manufacturing and Significant Clinical Trial Support

DALLAS, and SEOUL, South Korea, Feb. 19 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) and JCOM Ltd, an affiliate of DONG-A Pharmaceuticals, the premier pharmaceutical company in the Republic of Korea, today announced the signing of a definitive licensing agreement under which JCOM and DONG-A will manufacture, develop and commercialize Access' proprietary products ProLindac and MuGard for the Republic of Korea. ProLindac is Access' novel DACH platinum prodrug currently in Phase 2 clinical studies which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. MuGard is used for the management of oral mucositis, a debilitating side effect of many anticancer chemotherapy and radiation treatments, and has already received marketing allowance from US and European regulatory authorities.

Under the terms of the agreement JCOM will pay Access an upfront fee and subsequent milestone payments along with a double digit royalty upon commercialization of ProLindac and MuGard. In addition, in co-operation with Access, JCOM has committed to fund and execute a Phase 2 combination study for ProLindac in an indication to be determined by the Parties. This controlled Phase 2 combination study would cost up to $10 million if conducted in the US or Europe. Dong-A will be responsible for obtaining the necessary regulatory approvals for ProLindac and MuGard and commercializing the products in the Republic of Korea.

"We are very pleased to have JCOM and Dong-A as partners for ProLindac and MuGard," said Jeffrey B. Davis, Access' President & CEO. "We are excited about their commitment to rapidly start a Phase 2 study with ProLindac. This is the third major Phase 2 study to b
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... July 31, 2015 The Physician-Patient Alliance ... on July 28, 2015, "Surviving Your Hospital Stay: ... for Patient Safety." A sentence was ... read: "PPAHS is a member of ... Opioids. For more information on the National Coalition to ...
(Date:7/31/2015)...  Xcelience, a contract development and manufacturing organization ... structured cash investment in Powdersize, a ... and powder size classification within the pharmaceutical industry.  ... simultaneously adding a complete set of particle size ... "As we continue to build our ...
(Date:7/31/2015)... PORTLAND, Ore., July 31, 2015  Semler Scientific, Inc. ... and testing services to healthcare insurers and physician groups, ... June 30, 2015. "In the second ... over year revenue growth of 54%, quarter over quarter ... of the installed base of FloChec® units of 18%," ...
Breaking Medicine Technology:Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
... SAN DIEGO, Jan. 19, 2012 Sequenom, Inc. (NASDAQ: SQNM ... to market and other conditions, shares of its common stock in ... whether or when the offering may be completed, or as to ... & Company, Inc. is acting as sole book-running manager for the ...
... 19, 2012 Medicare officials should swiftly authorize a Special ... Medicare Part D prescription drug plan if the patient believes ... "preferred network" plan with inadequate pharmacy access, the National ... the start of the 2012 plan year on January 1, ...
Cached Medicine Technology:Sequenom Announces Proposed Public Offering of Common Stock 2Pharmacists Ask Medicare to Help Seniors Complaining About Inadequate Pharmacy Access in Medicare Prescription Drug Plans 2Pharmacists Ask Medicare to Help Seniors Complaining About Inadequate Pharmacy Access in Medicare Prescription Drug Plans 3
(Date:8/3/2015)... ... 03, 2015 , ... Recent reports by the American Medical Association show that ... their lives. Often time, low back and sciatic pain can happen as a result ... clinically with powerful pain medication or spinal surgery. Dynamic Health Care in Louisville, ...
(Date:8/2/2015)... ... August 03, 2015 , ... A new Phase I ... childhood cancers. The study is led by Kenneth G. Lucas, M.D. , chief ... Louisville in collaboration with colleagues at Kosair Children’s Hospital and in the ...
(Date:8/2/2015)... Orion, Clarkston, Metamora Michigan (PRWEB) , ... ... ... Pelvic Organ Prolapse (POP) results when the supportive muscles and connective tissues ... damaged. Causes of this weakness and damage include straining, heavy lifting, obesity, ...
(Date:8/1/2015)... In (PRWEB) , ... August 02, 2015 , ... ... month which will help the continuity of care for patients at this natural health ... of the unknown," Clinic Director Mary Heal said. "Heather's role is vital to our ...
(Date:8/1/2015)... ... 2015 , ... Western University of Health Sciences’ newest class ... growing percentage of U.S. physicians, and reflects the diversity of the communities where ... message delivered by John W. Becher, DO, president of the American Osteopathic Association, ...
Breaking Medicine News(10 mins):Health News:Dynamic Health Care in Louisville, KY, Offers a New and Cutting-Edge Therapy for Low Back & Leg Pain Sufferers 2Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Minimally Invasive and Robotic Treatment for Pelvic Organ Prolapse Now Available from the Specialists at Women’s Excellence in Bladder Control 2Health News:New Patient Advocate Enhances Natural Health Care 2Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5
... 24 The Baylor Charles A. Sammons Cancer Center has ... clinical trials cooperative groups in the United States. Funded by ... conducts clinical trials to prevent and treat cancer in adults, ... , "Joining this prestigious group will allow us to offer ...
... , Easter Seals New York and the New York State ... to local families in Port Jervis, New York , PORT ... Seals New York, in partnership with the New York State ... Easter Seals New York,s Child Development Center, Project Discovery in ...
... HARRISBURG, Pa., Nov. 24 Governor Edward G. Rendell ... flu were vaccinated during the weekend at public health ... health departments. , "With the federal government unable ... of H1N1 vaccine, distribution has been challenging," said Governor ...
... Ill., Nov. 24 Dr. Nelson Escobar, a physician with ... the James Brady Award. The award was presented to ... their annual conference on October 30, 2009. , According ... award in recognition of his expertise in addressing the complex ...
... may help ward off peripheral artery disease, researchers ... people aged 75 and older, the herbal supplement Ginkgo ... a new study finds. , There is some evidence ... leg-circulation problem known as peripheral artery disease, however. , ...
... PHILADELPHIA Researchers have found that hormones produced during ... of breast cancer. This protein, alpha-fetoprotein (AFP), may serve ... prevention of breast cancer, according to findings published in ... American Association for Cancer Research. "Hormones in ...
Cached Medicine News:Health News:Baylor Sammons Cancer Center Joins One of Nation's Largest Cancer Clinical Trials Groups 2Health News:Baylor Sammons Cancer Center Joins One of Nation's Largest Cancer Clinical Trials Groups 3Health News:Fraternal Order of Police Provides Food and Hope for Families in Port Jervis this Thanksgiving 2Health News:Governor Rendell Announces 100,000 At-Risk Pennsylvanians Vaccinated at H1N1 Public Health Clinics; Addresses Future Vaccine Distribution Plans 2Health News:Marianjoy Medical Group Physician Receives James Brady Award 2Health News:Ginkgo Won't Prevent Heart Attack, Stroke in Elderly 2Health News:Ginkgo Won't Prevent Heart Attack, Stroke in Elderly 3Health News:Protein from pregnancy hormone may prevent breast cancer 2